Pono Capital Corp (PONO) to Combine with Benuvia in $440M Deal
Pono (NYSE:PONO) has entered into a definitive agreement to acquire Benuvia, Inc., a drug developer focused on pharmaceutical cannabinoids, at an enterprise value of $440 million. The Arizona-based company owns an FDA approved cannabinoid drug SYNDROS (dronabinol oral solution CII), and synthetic cannabinoid manufacturing facilities in the U.S. The combined company is expected to tradeRead More